| Filed On | Filing |
|---|---|
| 09 Nov 2026 |
8-K: Results of Operations and Financial Condition
Company received HREC approval to initiate Phase 1/2 Strive™ study of EDIT-401 in patients with hyperlipidemia in Australia |
| 08 Oct 2026 |
8-K: Regulation FD Disclosure; Other Events
Phase 1/2 clinical trial of EDIT-401 cleared to initiate dosing in patients who require additional LDL-C lowering |
| 05 Aug 2026 |
8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation
EDIT-401 on track for CTN submission this month with data update in Q1 2027 |
| 18 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On June 17, 2026, Editas Medicine, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”). The following is a summary of matters voted on at the 2026 Annual Meeting. |
| 26 May 2026 |
8-K: Entry into a Material Definitive Agreement; Other Events
Editas Medicine, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [·] or its registered assigns (the “Holder”), is ent... |
| 26 May 2026 |
8-K: Other Events
On May 26, 2026, Editas Medicine, Inc. (the “Company”) notified TD Securities (USA) LLC (“TD Cowen”) that it was suspending and terminating the prospectus supplement, dated March 21, 2025, related to the sales agreement that the Company ... |
| 26 May 2026 |
8-K: Regulation FD Disclosure; Other Events
Editas Medicine Presents EDIT-401 Preclinical Data Demonstrating Robust Reductions in LDL-C, Lp(a), and ApoB in Non-Human Primates at the 94th European Atherosclerosis Society Congress |
| 14 May 2026 |
8-K: Regulation FD Disclosure; Other Events
Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting |
| 05 May 2026 |
8-K: Results of Operations and Financial Condition
EDIT-401, which demonstrated >90% mean LDL-C reduction in preclinical studies, on track to achieve early human proof-of-concept data by year-end 2026 |
| 07 Apr 2026 |
8-K: Changes in Registrant's Certifying Accountant
We have read Item 4.01 of Form 8-K dated April 7, 2026, of Editas Medicine, Inc. and are in agreement with the statements contained in the last sentence of the first paragraph and the second and third paragraphs on page 1 therein. We hav... |
| 27 Mar 2026 |
8-K: Regulation FD Disclosure; Other Events
Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference |
| 09 Mar 2026 |
8-K: Results of Operations and Financial Condition
Lead candidate, EDIT-401, which demonstrated >90% mean LDL-C reduction in preclinical studies, remains on track for IND/CTA submission by mid-2026 |
| 10 Nov 2025 |
8-K: Results of Operations and Financial Condition
In vivo preclinical proof-of-concept data presented at AHA and ESGCT demonstrating >90% LDL-C reduction in non-human primates supports EDIT-401’s potential as a best-in-class, one-time therapy |
| 09 Oct 2025 |
8-K: Regulation FD Disclosure; Other Events
Editas Medicine Reports In Vivo Proof-of-Concept Data for EDIT-401 at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress |
| 02 Sep 2025 |
8-K: Regulation FD Disclosure; Other Events
EDIT-401 achieved ~90% mean LDL-C reduction with single dose in non-human primates |
| 12 Aug 2025 |
8-K: Results of Operations and Financial Condition
Company to select lead development candidate in September; on track to file IND by mid-2026 and achieve human proof-of-concept by year-end 2026 |
| 12 Jun 2025 |
8-K: Regulation FD Disclosure; Other Events
Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in June |
| 02 Jun 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Amendments to Articles/Bylaws; Change in Fiscal Year +1 more
The purpose of this Amended and Restated 2015 Stock Incentive Plan (the “Plan”) of Editas Medicine, Inc., a Delaware corporation (the “Company”), is to advance the interests of the Company’s stockholders by enhancing the Company’s abilit... |
| 14 May 2025 |
8-K: Regulation FD Disclosure; Other Events
Editas Medicine Reports New In Vivo Data Highlighting the Potential of Editas’ Gene Upregulation Strategy in HSCs at the American Society of Gene and Cell Therapy Annual Meeting |
| 13 May 2025 |
8-K: Regulation FD Disclosure; Other Events
Editas Medicine Reports New In Vivo Proof of Concept Data in an Undisclosed Liver Target at the American Society of Gene and Cell Therapy Annual Meeting |
Loading...